Leveraging PACHE Strengths to Advance Cancer and Cancer Health Disparities Research

CURE Distinguished Scholar Seminar

CURE Distinguished Scholars Seminar Series

Tuesday, July 24, 2018 (2:00–3:30 pm)

Featured Speaker

Dana-Farber Cancer Institute
Associate Professor, Medicine, Harvard Medical School
Assistant Professor of Medicine, Medical Oncology Service, Dana-Farber Cancer Institute
Cancer Institute and Broad Institute
Director of the Joint Center for Precision Medicine and Co-leader of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center
Sr. Vice President, Global Development and Medical Affairs, Lilly Oncology
Eli Lilly and Company

Speaker Bio

Dr. Garraway is engaged in systematic genomic and functional studies to elucidate cellular pathways perturbed by recurrent genomic altercations in cancer, and to identify avenues for therapeutic intervention. Major areas of emphasis are melanoma and prostate cancer. His work involves the study of the mechanisms of carcinogenesis, resistance to targeted therapeutics, and the development of novel approaches to enable personalized cancer medicine. In recent years, Dr. Garraway’s primary focus has been to perform comprehensive genomic characterization of a large collection of patient-derived melanoma cultures and cell lines, and to apply both computational and experimental approaches to identify the critical target genes and pathways enacted by these alterations in an effort to develop “druggable” cellular targets.